ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Phase 3

Lenomorelin (Anamorelin)

Lenomorelin (Anamorelin)

Also known as: Anamorelin, ONO-7643, RC-1291, Adlumiz

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Lenomorelin (Anamorelin)

Selectively agonizes the GHS-R1a (ghrelin) receptor to stimulate GH release and appetite. Activates hypothalamic feeding centers through NPY/AgRP neurons.

Dosing Information

Half-Life

7-12 hours

Typical Dose

50–100 mg

Frequency

once daily, fasted

Cycle Length

12-24 weeks (as studied in clinical trials)

Administration Routes:
oral

Benefits

  • Oral administration with convenient dosing
  • Clinically proven appetite stimulation in cachectic patients
  • Increased lean body mass in cancer cachexia trials
  • Elevated GH and IGF-1 levels
  • Improved quality of life measures in clinical studies

Side Effects

Hyperglycemia and glucose intolerancemild
Nauseamild
Peripheral edemamild
QT interval prolongation at high dosesmild
Elevated liver enzymes in some patientsmild

Mechanism of Action

1

Selectively agonizes the GHS-R1a (ghrelin) receptor to stimulate GH release and appetite

2

Activates hypothalamic feeding centres through NPY/AgRP neurons

3

Promotes positive nitrogen balance and lean mass accretion via GH/IGF-1 axis activation

Contraindications

Do not use this peptide if any of the following apply:

  • Significant cardiac conduction disorders (QT prolongation risk)
  • Pregnancy or breastfeeding
  • Uncontrolled diabetes
  • Hepatic impairment

Storage & Reconstitution

Unreconstituted (Powder)

Temperature15–25°C (59–77°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature15–25°C (59–77°F)
Duration2-4 weeks

Research Summary

Phase 3

Anamorelin completed multiple Phase III trials (ROMANA 1, 2, and 3) demonstrating significant increases in lean body mass and body weight in patients with non-small cell lung cancer cachexia. It was approved in Japan in 2021 under the brand name Adlumiz. FDA approval was not pursued after the EMA declined authorization citing improvements in lean mass but insufficient evidence for functional improvement.

Frequently Asked Questions

Common questions about Lenomorelin (Anamorelin)

UK-Specific Information

Exclusive data points and guidance for UK residents using Lenomorelin (Anamorelin)

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok